Sapio Sciences collaborates with Waters Corporation to improve efficiency of laboratory operations

The advanced connectivity of Sapio LIMS with waters_connect for Quantitation liquid chromatography mass spectrometry (LC-MS) software

Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer d

Bio-Rad demonstrates leadership position in the oncology market at Association for Molecular Pathology 2024

Strength of ddPCR™ Products, Including IVDR Certification, Strategic Collaborations in Molecular Residual Disease Monitoring, and Large Methylation Assay Library, Support Company’s Oncology Strategy

Mursla Bio joins leading European consortium to advance clinical applications based on extracellular vesicle science

Selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics Consortium funded by Horizon Europe, the largest European research and innovation program

Cambridge, UK, and Bo

SolasCure and U.S. Army Institute of Surgical Research collaborate for combat wound care

The collaboration will evaluate Aurase Wound Gel for the treatment of infected wounds in combat field care scenarios

Cambridge, UK and Texas, USA, 06 November 2024: SOLASCURE Ltd, a biotechnology company developing a novel treatment

Sapio Sciences expands collaboration with AWS to advance science-aware AI vision

Collaboration enables customers to securely and confidently use AI to accelerate drug research and discovery

VALANX Biotech and Fina Biosolutions introduce ClickCRM for rapid conjugate vaccine development

Joint licensing agreement to commercialize ready-to-conjugate vaccine carrier protein CRM197 will enable rapid development of conjugate vaccines

Kadans Science Partner breaks ground at new purpose-built commercial science facilities at Merlin Place, North Cambridge

Breaking ground ceremony brings together key stakeholders to celebrate progress in development of new bespoke laboratory facilities Latest facilities extend Kadans’ coverage to include north of Cambridge in addition to site at the Babraham Research Campus

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna’s lead drug candidate Study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile CAL101 is now entering Phase 2 clinical development

Ellison Institute of Technology Los Angeles Accelerates Cancer Research with Sapio LIMS

Innovative research institute streamlines operations and enhances collaboration with unified laboratory informatics platform

Baltimore, MD, 22 October 2024 – Sapio Sciences, the science-aware™ lab informa

Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities

Enhancements support ADA and NAb testing workflows, boosting lab efficiency and regulatory compliance for drug development

Baltimore, MD – Sapio Sciences, the science-aware™

Shift Bioscience raises $16M to advance cell simulation AI platform

Investment led by BGF, with support from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner Seed funding will accelerate development of Shift Bioscience’s platform for identification of safe rejuvenation genes, a fundamental step forward in the

Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal assets targeting multiple GPCRs and Ion

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Collaboration will combine Alleo’s AI-based platform with Ubiquigent’s expertise in the DUB space to advance DUB-focused preclinical programmes

Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Executive appointments will drive growth strategy and progression of clinical pipeline

Bio-Rad launches high-precision Vericheck ddPCR Empty-Full Capsid Kit to advance development of safe and effective gene therapies

Vericheck ddPCR Empty-Full Capsid Kit Combines Measuring Viral Titer and Capsid Titer, Providing a High-Precision Assessment for Critical Quality Attributes of Both Protein and DNA in Droplets

Mosaic Therapeutics appoints Dr Barry Davies as CSO

Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform

C

CrestOptics and Leica Microsystems announce strategic collaboration to expand capabilities of spinning disk microscopy

Collaboration to incorporate CICERO spinning disk imaging unit within THUNDER Imager Cell system New system launched at Neuroscience 2024 (5th-9th October, Chicago, I

H.E.L Group introduces iso-BTC e to advance semiconductor technologies

New specialized isothermal calorimeter enables direct measurement of heat dissipation and optimization of thermal management and design

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services

FUJIFILM Irvine Scientific Adds Key Products To Its Life Sciences Portfolio From FUJIFILM Wako Chemicals U.S.A.

Additional products in lab automation, lab chemicals and LAL expand complete solutions available directly from FUJIFILM Irvine Scientific to customers in US and Europe Sales agreement aligns business and commercial operations to maximize customer benefit

Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001

ETD001 is a novel, first in class blocker of the epithelial sodium channel (ENaC) aimed at treating people with cystic fibrosis without current effective therapies ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025

Steritas’ Pediatric Glucocorticoid Toxicity Index used by Alder Hey and Liverpool Trials Centre to assess steroid toxicity in children with juvenile idiopathic arthritis

Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children

FUJIFILM Irvine Scientific develops Oceo Rover: the first automated single-use hydration system for media and buffers

Oceo Rover automates and simplifies hydration of powdered media and buffers, to optimize bioprocessing workflows Automated system harnesses single-use technology to reduce risks associated with variability, contamination and safety within biopharmaceutical manufactur

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

High performance two-plasmid production system achieves E12 vg/mL unconcentrated titers AI-driven design tools to improve expression precision, efficacy, and manufacturability

Boston, Massachusetts, 18 Sep 2024: Asimov, the synth